Literature DB >> 2500434

Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells.

Y Singh1, S H Leppla, R Bhatnagar, A M Friedlander.   

Abstract

Anthrax lethal toxin consists of two separate proteins, protective antigen and lethal factor (LF). Certain macrophages and a mouse macrophage-like cell line, J774A.1, are lysed by low concentrations of lethal toxin. In contrast, another macrophage cell line, IC-21, and all other cell types tested were resistant to this toxin. To discover the basis for this difference, each step in the intoxication process was examined. No differences between sensitive and resistant cells were found in receptor binding or proteolytic activation of protective antigen, steps that are required prior to LF binding. To determine whether resistance results from a defect in translocation to the cytosol, we introduced LF into J774A.1 and IC-21 cells and a nonmacrophage cell line (L6 myoblast) by osmotic lysis of pinocytic vesicles. Only J774A.1 cells were lysed; no effect was observed in IC-21 and L6 cells. These results suggest that resistant cells either lack the intracellular target of LF or fail to process LF to an active form. The relatively low potency of LF introduced into J774A.1 cells by osmotic lysis suggests that protective antigen may also be required at a stage subsequent to endocytosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2500434

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin.

Authors:  S F Little; S H Leppla; A M Friedlander
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  Killing of macrophages by anthrax lethal toxin: involvement of the N-end rule pathway.

Authors:  Katherine E Wickliffe; Stephen H Leppla; Mahtab Moayeri
Journal:  Cell Microbiol       Date:  2008-02-05       Impact factor: 3.715

4.  Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome.

Authors:  Katherine E Wickliffe; Stephen H Leppla; Mahtab Moayeri
Journal:  Cell Microbiol       Date:  2007-09-10       Impact factor: 3.715

5.  Heat shock inhibits caspase-1 activity while also preventing its inflammasome-mediated activation by anthrax lethal toxin.

Authors:  Tera C Levin; Katherine E Wickliffe; Stephen H Leppla; Mahtab Moayeri
Journal:  Cell Microbiol       Date:  2008-08-28       Impact factor: 3.715

6.  Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.

Authors:  Jason E Comer; Ashok K Chopra; Johnny W Peterson; Rolf König
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Neutralization of B. anthracis toxins during ex vivo phagocytosis.

Authors:  Olga Tarasenko; Ashley Scott; April Jones; Lee Soderberg; Pierre Alusta
Journal:  Glycoconj J       Date:  2012-09-15       Impact factor: 2.916

8.  Polymeric glycoconjugates protect and activate macrophages to promote killing of Bacillus cereus spores during phagocytosis.

Authors:  Olga Tarasenko; Elizabeth Burton; Lee Soderberg; Pierre Alusta
Journal:  Glycoconj J       Date:  2008-01-17       Impact factor: 2.916

9.  Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin.

Authors:  Jennifer L Bromberg-White; Elissa Boguslawski; Nicholas S Duesbery
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

10.  Anthrax lethal factor represses glucocorticoid and progesterone receptor activity.

Authors:  Jeanette I Webster; Leonardo H Tonelli; Mahtab Moayeri; S Stoney Simons; Stephen H Leppla; Esther M Sternberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.